PAI
Palo Alto Investors Portfolio holdings
AUM
$470M
This Quarter Return
+5.9%
1 Year Return
+2.57%
3 Year Return
+93.77%
5 Year Return
+190.64%
10 Year Return
+955.02%
AUM
$1.17B
AUM Growth
+$1.17B
(-7.3%)
Cap. Flow
-$96M
Cap. Flow
% of AUM
-8.18%
Top 10 Holdings %
Top 10 Hldgs %
89.35%
Holding
33
New
1
Increased
11
Reduced
5
Closed
4
Top Buys
| 1 |
RVNC
Revance Therapeutics, Inc.
RVNC
|
$16.2M |
| 2 |
Acadia Pharmaceuticals
ACAD
|
$11.1M |
| 3 |
Amicus Therapeutics
FOLD
|
$7.89M |
| 4 |
STAAR Surgical
STAA
|
$6.95M |
| 5 |
Align Technology
ALGN
|
$6.39M |
Top Sells
| 1 |
ABMD
Abiomed Inc
ABMD
|
$121M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
$9.36M |
| 3 |
Vanda Pharmaceuticals
VNDA
|
$7.97M |
| 4 |
GRTS
Gritstone bio, Inc. Common Stock
GRTS
|
$5.74M |
| 5 |
CLVS
Clovis Oncology, Inc.
CLVS
|
$5.32M |
Sector Composition
| 1 | Healthcare | 98.97% |
| 2 | Financials | 1.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
BioMarin Pharmaceuticals
BMRN
$11.2B
| $195M | 16.64% | 1,885,811 -90,454 | -5% | -$9.36M |
|
2
United Therapeutics
UTHR
$13.8B
| $174M | 14.83% | 625,414 -8,120 | -1% | -$2.26M |
|
|
3
Amicus Therapeutics
FOLD
$2.34B
| $128M | 10.92% | 10,493,722 +645,948 | +7% | +$7.89M |
|
4
Insmed
INSM
$28.8B
| $117M | 10% | 5,871,291 +30,893 | +0.5% | +$617K |
|
5
Biogen
BIIB
$19.4B
| $105M | 8.97% | 380,082 +19,101 | +5% | +$5.29M |
|
6
Prothena Corp
PRTA
$441M
| $99.9M | 8.52% | 1,658,577 +8,800 | +0.5% | +$530K |
|
|
RVNC
7
DELISTED
Revance Therapeutics, Inc.
RVNC
| $97.5M | 8.32% | 5,283,609 +878,570 | +20% | +$16.2M |
|
|
8
STAAR Surgical
STAA
$1.36B
| $60.2M | 5.13% | 1,240,077 +143,195 | +13% | +$6.95M |
|
|
9
Acadia Pharmaceuticals
ACAD
$4.38B
| $37.8M | 3.23% | 2,376,369 +698,173 | +42% | +$11.1M |
|
|
SAGE
10
DELISTED
Sage Therapeutics
SAGE
| $32.7M | 2.79% | 856,517 +5,108 | +0.6% | +$195K |
|
11
Karyopharm Therapeutics
KPTI
$61.7M
| $19.2M | 1.64% | 5,655,676 +34,143 | +0.6% | +$116K |
|
12
Alkermes
ALKS
$4.78B
| $15.8M | 1.34% | 603,400 | – | – |
|
|
13
Align Technology
ALGN
$10.3B
| $15.7M | 1.34% | 74,605 +30,300 | +68% | +$6.39M |
|
14
Syndax Pharmaceuticals
SNDX
$1.41B
| $15.6M | 1.33% | 612,600 | – | – |
|
15
AnaptysBio
ANAB
$569M
| $13.4M | 1.14% | 431,024 | – | – |
|
16
eHealth
EHTH
$118M
| $12M | 1.03% | 2,484,479 +506,486 | +26% | +$2.45M |
|
|
17
Vanda Pharmaceuticals
VNDA
$279M
| $8.04M | 0.69% | 1,087,607 -1,078,549 | -50% | -$7.97M |
|
18
Cytokinetics
CYTK
$4.23B
| $5.12M | 0.44% | 111,717 | – | – |
|
19
Kezar Life Sciences
KZR
$28.9M
| $4.62M | 0.39% | 656,200 | – | – |
|
|
PRVB
20
DELISTED
Provention Bio, Inc. Common Stock
PRVB
| $4.13M | 0.35% | 390,800 | – | – |
|
21
Travere Therapeutics
TVTX
$1.56B
| $3.49M | 0.3% | 166,069 | – | – |
|
|
GRTS
22
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $2.3M | 0.2% | 666,127 -1,664,377 | -71% | -$5.74M |
|
|
PKBO
23
DELISTED
Peak Bio, Inc. Common Stock
PKBO
| $2.02M | 0.17% | +497,528 | New | +$2.02M |
|
24
Mirum Pharmaceuticals
MIRM
$3.71B
| $1.26M | 0.11% | 64,700 | – | – |
|
25
Aldeyra Therapeutics
ALDX
$351M
| $1.12M | 0.1% | 160,800 | – | – |
|